Changchun High-Tech Industry (Group) Co: Revenue and net profit fell significantly in Q3 2024, with only Huakang Pharma showing growth

About this update from Changchun High-tech Industry (group) Co., Ltd. Class A

Q3 2024 saw revenue and net profit decline sharply year-over-year, with most subsidiaries underperforming except Huakang Pharma. Cash flow and margins weakened, while management expenses and non-operating costs rose.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Changchun High-tech Industry (group) Co., Ltd. Class A